Galecto Finalizes $295.9M Public Offering to Fund Phase 3 Development

summarizeSummary

Galecto, Inc. entered into a definitive underwriting agreement for a public offering of 16.64 million shares at $19.00 per share, raising approximately $295.9 million in net proceeds to fund its DMR-001 Phase 3 development.

check_boxKey Events

• Underwriting Agreement Signed

  Galecto, Inc. entered into an underwriting agreement with Jefferies LLC and Leerink Partners LLC on February 10, 2026, for a public offering.

• Offering Size and Pricing Finalized

  The company will sell 14,473,685 shares of common stock at a public offering price of $19.00 per share. The underwriters' 30-day option to purchase an additional 2,171,052 shares was exercised in full on February 11, 2026, bringing the total shares to 16,644,737.

• Substantial Capital Raise

  The offering is expected to generate approximately $295.9 million in net proceeds for the company, after deducting underwriting discounts and estimated expenses.

• Use of Proceeds for Phase 3 Development

  The net proceeds, combined with existing cash, are expected to fund operations into Phase 3 development of DMR-001.

auto_awesomeAnalysis

This 8-K filing provides the definitive terms of a substantial public offering, following the preliminary disclosures and the 424B5 filed concurrently. Galecto, Inc. has secured approximately $295.9 million in net proceeds by selling 16.64 million shares (including the fully exercised option) at $19.00 per share. While this capital infusion is critical for the company to fund its operations into Phase 3 development of DMR-001, it comes at the cost of extreme dilution for existing shareholders, given the company's current market valuation. The offering price is at a discount to the current stock price. This financing event is crucial for the company's operational runway, especially following the recent acquisition of Damora Therapeutics and a CEO transition, but its highly dilutive nature is a significant negative for equity holders.